All In Biotech

Drug Trial Radar · NCT05018702

ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

A Prospective, Single-arm, Single-center Phase II Clinical Study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-AS269 Conjugate (ARX788) in the Treatment of HER2-positive Breast Cancer Patients With Brain Metastases

Last checked: Nov 19, 2026Latest source record: Jun 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

32

Planned (sponsor's estimate)

Start

Jul 14, 2021

Primary completion

Dec 30, 2022

Study completion Jun 30, 2023

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose Disease is resistant or refractory to Tyrosine kinase inhibitors (TKI).

Conditions

  • HER2-positive, Metastatic Breast Cancer

Interventions

  • ARX788Drug

    1.5 mg/kg IV infusion on Day 1 of each 21-day treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Central nervous system (CNS) clinical benefit rate (CBR)Time frame: 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.